Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.6 USD | -2.85% | +0.35% | +120.53% |
May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
Business Summary
Number of employees: 110
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antisense Oligonucleotide
100.0
%
| 12 | 100.0 % | 9 | 100.0 % | -29.22% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 12 | 100.0 % | 9 | 100.0 % | -29.22% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Isabel Aznarez
FOU | Founder | 52 | 14-05-31 |
Edward Kaye
CEO | Chief Executive Officer | 74 | 17-09-30 |
Barry Ticho
CTO | Chief Tech/Sci/R&D Officer | 64 | 17-09-30 |
Huw Nash
COO | Chief Operating Officer | 57 | 14-09-30 |
Eric Rojas
IRC | Investor Relations Contact | - | - |
Jonathan Allan
LAW | General Counsel | - | - |
Shamim Ruff
LAW | General Counsel | 64 | 18-11-30 |
Joan Wood
HRO | Human Resources Officer | - | 19-10-15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 15-08-31 |
Edward Kaye
CEO | Chief Executive Officer | 74 | 17-09-30 |
Seth Harrison
CHM | Chairman | 63 | 15-06-30 |
Ian Smith
BRD | Director/Board Member | 58 | 23-09-18 |
Garry Menzel
BRD | Director/Board Member | 59 | 20-08-12 |
Julie Smith
BRD | Director/Board Member | 53 | 20-06-03 |
Director/Board Member | 52 | 19-06-13 | |
Arthur Tzianabos
BRD | Director/Board Member | 60 | 18-09-16 |
Adrian Krainer
FOU | Founder | 65 | 14-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,119,860 | 49,697,530 ( 95.35 %) | 0 | 95.35 % |
Company contact information
Stoke Therapeutics, Inc.
45 Wiggins Avenue
01730, Bedford
+781 430 8200
http://www.stoketherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+120.53% | 605M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- STOK Stock
- Company Stoke Therapeutics, Inc.